Top Markets
#1 Black Phoenix Black Phoenix +736.90%
#2 Beam Beam +33.24%
#3 SAFEcoin SAFEcoin +19.80%
#4 THORChain THORChain +18.13%
#5 TENDIES TENDIES +18.02%
#6 Tutorial Tutorial +14.96%
#7 EfficientFrontier EfficientFrontier +14.67%
#8 Bless Bless +14.24%
#9 THORChain Yield THORChain Yield +13.45%
#10 Versatize Coin Versatize Coin +12.49%
Coin of the day
Black Phoenix Black Phoenix
Impostazioni
Lingua
ITALIANO
Valuta
USD
Tema
Myovant Sciences Ltd. Myovant Sciences Ltd.

Myovant Sciences Ltd.

MYOV
Classifica tra le azioni #5521
Myovant Sciences Ltd. is a biopharmaceutical company focused on innovating... Myovant Sciences Ltd. is a biopharmaceutical company focused on innovating healthcare solutions for both women and men. Its flagship product is relugolix, an orally administered, once-daily small molecule that functions as a gonadotropin-releasing hormone (GnRH) receptor antagonist. This medication is indicated for conditions such as heavy menstrual bleeding caused by uterine fibroids, pain associated with endometriosis, and advanced prostate cancer. The company is also developing MVT-602, an oligopeptide kisspeptin agonist, currently in Phase II clinical trials for treating female infertility within assisted reproductive procedures. Myovant collaborates with Pfizer Inc. for the development and commercialization of relugolix across oncology and women's health sectors. Incorporated in 2016, initially as Roivant Endocrinology Ltd. before rebranding to Myovant Sciences Ltd. in May of that year, the firm is based in London, United Kingdom, and operates as a subsidiary of Sumitovant Biopharma Ltd.
Prezzo delle azioni
$26.98
Ultima sincronizzazione: 2023-03-09
Capitalizzazione di mercato
$2.62B
Variazione (1 giorno)
-0.04%
Variazione (1 anno)
0.00%
Paese
GB
Scambia Myovant Sciences Ltd. (MYOV)

Categoria

Healthcare
Utile per Myovant Sciences Ltd. (MYOV)
Utile nel 2026 TTM: 0
Secondo gli ultimi rapporti finanziari di Myovant Sciences Ltd., gli utili attuali della società sono 0. Nel 2026, la società ha registrato un utile di 0, uguale a agli utili del 2026, che erano di 0. Gli utili mostrati in questa pagina sono quelli prima degli interessi e delle imposte, ovvero EBIT.
Storico degli utili di Myovant Sciences Ltd. dal 2026 al 2026
Utile alla fine di ogni anno
Anno Utile Cambia
Non abbastanza dati per le date fornite.
Utile per aziende simili o concorrenti
Azienda Utile Differenza negli utili Il paese
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
$5.27B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
$1.95B -
NL
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
$-3.09B -
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
$-4.02B -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
- -
CH